Lexicon is pursuing drug targets in five therapeutic areas including oncology, gastroenterology, immunology, metabolism, and ophthalmology.

[5] The information collected from this program is stored in the company’s LexVision database, which contains almost 5,000 gene knockouts studied.

The conclusion of this analysis was that, in most cases, there was a direct correlation when comparing the physiological characteristics, or phenotypes, of knockout mice to the therapeutic effect of the 100 best-selling drugs of 2001.

[9] The tremendous utility of knockout mouse technology was recognized in 2007 with the Nobel Prize in Physiology or Medicine to Drs.

Dr. K. Barry Sharpless, who was awarded the 2001 Nobel Prize in Chemistry,[11] pioneered this set of powerful and reliable tools for the rapid synthesis of novel compounds.

Lexicon’s medicinal chemists design these libraries by analyzing the chemical structures of drugs that have been proven safe and effective against human disease and using that knowledge in the design of scaffolds and chemical building blocks for the generation of large numbers of new drug-like compounds.